January 2025 in “Journal of Education Health and Sport” This study reviewed existing methods to prevent chemotherapy-induced hair loss, highlighting FDA-approved scalp cooling as currently the most effective yet still insufficient solution and noting the need for more reliable treatments to better support cancer patients.
20 citations
,
September 2013 in “Anti-Cancer Drugs” In this study, PTH-CBD effectively prevented and partially reversed chemotherapy-induced alopecia in mice, with pretreatment offering a better cosmetic outcome compared to therapeutic administration after hair loss onset.
September 2025 in “PubMed” In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.
19 citations
,
June 2020 in “International Journal of Dermatology” In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.
57 citations
,
March 2011 in “The American Journal of Dermatopathology” This study found that permanent alopecia can occur after certain chemotherapy treatments and presents as nonscarring hair loss similar to androgenetic alopecia, with specific histological features that could be misdiagnosed without proper clinicopathological correlation.
